Skip to main content
Log in

Trimethoprim-Induced Hyperkalaemia

Clinical Data, Mechanism, Prevention and Management

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Cotrimoxazole (trimethoprim-sulfamethoxazole) is a combination antimicrobial that is frequently used to treat a wide variety of infections. Only recently has hyperkalaemia been recognised as a relatively common complication of therapy with trimethoprim. Hyperkalaemia has been demonstrated to occur with the administration of both high and standard dosages of trimethoprim.

The recognition of this disorder of potassium homeostasis prompted the investigation and ultimate description of the mechanism by which trimethoprim causes hyperkalaemia. Trimethoprim was found to reduce renal potassium excretion through the competitive inhibition of epithelial sodium channels in the distal nephron, in a manner identical to the potassium-sparing diuretic amiloride. Increased risk for hyperkalaemia with trimethoprim treatment appears to be related to both higher dosages and underlying renal impairment. It is probable that other disturbances in potassium homeostasis, such as hyopoaldosteronism and treatment with medications that impair renal potassium excretion, are also risk factors for hyperkalaemia with trimethoprim therapy.

Prevention of this adverse reaction depends upon recognition of patients at risk of developing hyperkalaemia as well as proper dosage selection of trimethoprim for the patient’s prevailing glomerular filtration rate. Management of hyperkalaemia often mandates discontinuation of the drug, volume repletion with isotonic fluids, and other therapies specific to hyperkalaemia. In circumstances where continued treatment with trimethoprim is required, induction of high urinary flow rates with intravenous fluids and a loop diuretic, as well as alkalinisation of the urine, have been shown to block the antikaliuretic effect of trimethoprim on distal nephron cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Lawson DH, Jick H. Adverse reactions to co-trimoxazole. Am J Med Sci 1978; 275: 53–7

    Article  CAS  PubMed  Google Scholar 

  2. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4: 426–8

    Article  CAS  PubMed  Google Scholar 

  3. Jawetz E. Sulfonamides and trimethoprim. In: Katzung BG, editor. Basic and clinical pharmacology. 2nd ed. Los Altos, California: Lange, 1984: 554–8

    Google Scholar 

  4. Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis 1982; 4: 429–33

    Article  CAS  PubMed  Google Scholar 

  5. Richmond JM, Whitworth JA, FairleyKF, et al. Co-trimoxazole nephrotoxicity [letter]. Lancet 1979; I: 493

  6. Cryst C, Hammar SP. Acute granulomatous interstitial nephritis due to co-trimoxazole. Am J Nephrol 1988; 8: 483–8

    Article  CAS  PubMed  Google Scholar 

  7. Berglund F, Killander J, Pompeius R. Effect of trimethoprimsulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802–8

    CAS  PubMed  Google Scholar 

  8. Choi MJ, Fernandez PC, Coupaye-Gerard B, et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328: 703–6

    Article  CAS  PubMed  Google Scholar 

  9. Velçzquez H, PerazellaMA,Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119: 296–301

    Google Scholar 

  10. Greenberg S, Reiser IW, Chou SY, et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119: 291–5

    Article  CAS  PubMed  Google Scholar 

  11. Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46: 187–92

    CAS  PubMed  Google Scholar 

  12. Kaufman AM, Hellman G, Abramson RG. Renal salt wasting and metabolic acidosis with trimethoprim-sulfamethoxazole therapy. Mt Sinai J Med 1983; 50: 238–9

    CAS  PubMed  Google Scholar 

  13. Kalin MF, Poretsky L, Seres DS, et al. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987; 82: 1035–8

    Article  CAS  PubMed  Google Scholar 

  14. Medina I,Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl JMed 1990; 323: 776–82

    CAS  Google Scholar 

  15. Canaday DH, Johnson JR. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med 1994; 120: 437–8

    Article  CAS  PubMed  Google Scholar 

  16. ModestGA, Price B,Mascoli N. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole [letter]. Ann Intern Med 1994; 120: 437

  17. Pennypacker LC, Mintzer J, Pitner J. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole [letter]. Ann Intern Med 1994; 120: 437

    Article  CAS  PubMed  Google Scholar 

  18. Smith GW, Cohen SB. Hyperkalemia and non-oliguric renal failure associated with trimethoprim. BMJ 1994; 308: 454

    Article  CAS  PubMed  Google Scholar 

  19. Marinella MA. Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole. Am J Med Sci 1995; 310: 115–9

    CAS  PubMed  Google Scholar 

  20. Alappan R, Perazella MA, Buller GK Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124: 316–20

    Article  CAS  PubMed  Google Scholar 

  21. 21 Bugge JF. Severe hyperkalemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. J Intern Med 1996; 240 249–52

    Article  CAS  PubMed  Google Scholar 

  22. Elisaf M, Terrovitou C, Tomos P, et al. Severe hyperkalemia after cotrimoxazole administration in a patient with hyporeninemic hypoaldosteronism. Nephrol Dial Transplant 1997; 12: 1254–5

    Article  CAS  PubMed  Google Scholar 

  23. Safrin S, Finkelstein DM. Comparison of oral agents for the treatment of Pneumocystis carinii pneumonia [letter]. Ann Intern Med 1997; 126: 407–8

    Article  Google Scholar 

  24. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: Is hyperkalemia a significant problem? Am J Nephrol 1999; 19 (3): 389–94

    Article  CAS  PubMed  Google Scholar 

  25. Funai N, Shimamoto Y,MatsuzakiM, et al. Hyperkalemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. Haematologia 1993; 25: 137–41

    CAS  Google Scholar 

  26. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1996; 124: 792–802

    Article  CAS  PubMed  Google Scholar 

  27. Perazella MA. Comparison of oral agents for the treatment of Pneumocystis carinii pneumonia [letter]. Ann Intern Med 1997; 126: 407

    Article  CAS  PubMed  Google Scholar 

  28. Reiser IW, Chou S, Brown MI, et al. Reversal of trimethopriminduced antikaliuresis. Kidney Int 1996; 50: 2063–9

    Article  CAS  PubMed  Google Scholar 

  29. Schreiber M, Schlanger LE, Chen CB, et al. Antikaliuretic action of trimethoprim isminimized by raising urine pH.Kidney Int 1996; 49: 82–7

    Article  CAS  PubMed  Google Scholar 

  30. Eiam-ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996; 49: 1372–8

    Article  CAS  PubMed  Google Scholar 

  31. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med 1997; 12: 646–56

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark A. Perazella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perazella, M.A. Trimethoprim-Induced Hyperkalaemia. Drug-Safety 22, 227–236 (2000). https://doi.org/10.2165/00002018-200022030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200022030-00006

Keywords

Navigation